Triple-Drug cocktail shows promise for rare kidney cancers
Disease control
Ongoing
This study tests whether combining three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow or shrink advanced kidney cancers that are not the common clear-cell type. About 60 adults with cancers like papillary or chromophobe RCC that have spread will receive the com…
Phase: PHASE2 • Sponsor: Bradley A. McGregor, MD • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC